Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Consensus Rating of “Buy” from Analysts

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) has been given a consensus rating of “Buy” by the eight ratings firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company.

BAYRY has been the subject of several analyst reports. Jefferies Financial Group raised shares of Bayer Aktiengesellschaft to a “hold” rating in a report on Friday, May 29th. Zacks Research upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 10th. Deutsche Bank Aktiengesellschaft upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a research report on Thursday, July 2nd. Finally, DZ Bank upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th.

Bayer Aktiengesellschaft Stock Performance

Shares of OTCMKTS BAYRY opened at $13.60 on Thursday. The firm has a market capitalization of $53.45 billion, a price-to-earnings ratio of -21.25, a PEG ratio of 4.48 and a beta of 0.55. Bayer Aktiengesellschaft has a one year low of $7.19 and a one year high of $15.23. The business has a fifty day simple moving average of $11.72 and a 200 day simple moving average of $11.86. The company has a current ratio of 1.05, a quick ratio of 0.70 and a debt-to-equity ratio of 1.06.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its earnings results on Tuesday, May 12th. The company reported $0.79 EPS for the quarter, topping the consensus estimate of $0.64 by $0.15. Bayer Aktiengesellschaft had a positive return on equity of 17.61% and a negative net margin of 4.75%.The business had revenue of $15.73 billion during the quarter, compared to the consensus estimate of $15.77 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. Sell-side analysts expect that Bayer Aktiengesellschaft will post 1.25 EPS for the current year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.